AstraZeneca Plc agreed to buy the Belgian biotech EsoBiotec for as much as $1 billion in a deal that will see the British ...

Celex Oncology's first attendance at Bio-Europe Spring 2025 follows their recent win at the 2024 EIT Health Catapult ...

This oversubscribed Series A funding round was led by General Catalyst with additional investment from new investors, British ...

Maxion Therapeutics has secured $72 million in an oversubscribed Series A raise, with Eli Lilly pitching in, to advance its ...

The deal includes the Belgian biotech’s vivo cell-therapy platform, which modifies immune cells within the patient’s body, ...

The high-profile stockpicker is the eye disorder treatment hopeful’s biggest shareholder. Ahead of the results of a crucial ...

COAST REGION: TANZANIA is set to become a key player in Africa’s fight against malaria through a major investment in an ...

Equities research analysts at HC Wainwright boosted their Q1 2025 earnings per share estimates for Legend Biotech in a ...

Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

All eyes are on Alnylam as the company awaits entry into the transthyretin amyloid cardiomyopathy market, which currently ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Chinese drug maker Akeso, whose new cancer drug has outperformed a leading Western peer in clinical studies, is being hailed ...